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Phorbol myristate acetate  [12-O-tetradecanoyl-phorbol-13-acetate(PMA)] is 
one of several biologically active substances derived from croton oil,  which 
potentiate the action of a carcinogen in inducing epidermoid tumors of mouse 
skin (cf.  reference 1 for review).  Interest in the role of immune response in 
epidermal carcinogenesis prompted us to investigate possible effects of PMA on 
lymphocytes. We observed that PMA is a potent mitegen for human peripheral 
blood lymphocytes (2), an observation confirmed by several laboratories (3-6). In 
this report, we present evidence that PMA approximates phytohemagglutinin 
(PHA) in its mitogenic potency, yet acts selectively on a T-lymphocyte subpepu- 
lation that has high affinity for sheep erythrocytes (SRBC) and is distinct from 
that responsive to PHA. 
Materials and Methods 
Human peripheral blood lymphocytes (PBL) were  separated by centrifugation on a  Ficoll- 
Hypaque gradient and cultured in tubes as previously described (7), PMA dissolved in dimethyl- 
sulphoxide (DMSO) was kindly provided by Dr.  A  Sivak, New York University, New  York. 
Purified PHA (PHA MR-68-69), concanavalin  A (Con A), and pokeweed mitogen (PWM) were used 
at the optimal mitogenic concentrations. Separation of T lymphocytes was performed by the SRBC 
rosette technique (8). Ablation of proliferating lymphocytes was performed using the 5'-bromode- 
oxyuridine (BUdR) and light technique previously described (7). All experimental manipulations 
were performed in triplicate and repeated at least twice. DMSO, the solvent vehicle for PMA, was 
inactive at equivalent concentrations in each of the experimental situations. 
Results 
Fig.  1 A  presents the dose-response characteristics  of PMA  stimulation of 
human PBL proliferation. Maximal stimulation is observed at 100 ng/ml. Varia- 
ble stimulation occurs at 1,000 ng/ml, and inhibition at greater concentrations. 
Fig.  1 B  depicts the  time-course of the  PMA response.  Peak  stimulation is 
observed  at  4-5  days  of culture,  depending on  the  concentration of PMA. 
Comparable responses for PHA under these conditions are obtained at 3/zg/ml, 
peaking at 3 days (data not shown). In 11 experiments directly comparing PHA 
(3/zg/ml) and PMA (100 ng/ml) at 72 h of culture, the incorporation of  thymidine 
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FIG. i.  Incorporation of [ZH]thymidine by human PBL after  stimulation with PMA. (A) 
Dose-response curve. (B) Kinetics of  the response using 100 ng/ml (©--©) or 1,000  ng/ml 
(©-.-©) of PMA. 
was 280  "4- 24  x  103 cpm/culture and 234 _+ 26  x  103 cpm/culture, respectively. 
While the PMA response averages four-fifths of the PHA response, great varia- 
bility  in  the  relative  responses  was  noted,  and  in  5  of 11  individuals  the 
stimulation by PMA was greater than the stimulation induced by an optimal 
dose of PHA.  These data suggested that PMA and PHA might be acting on 
different lymphoid populations.  The following experiments were designed to 
obtain insight into the population of lymphocytes responding to PMA. 
To further compare the response of lymphocytes to PHA and PMA, a BUdR 
and light technique was used to ablate the cells proliferating in response to 
stimulation by each of  the mitogens. With this method, the response to PHA, for 
example,  can be  reduced by  approximately  75%  and,  more  importantly,  no 
further stimulation can be produced by readdition of PHA or another mitogen 
acting on the same population of PBL (e.g., Con A) (7). The employment of this 
technique with PMA is depicted in Fig. 2.  When the PHA response is ablated 
with BUdR and light, the PMA response is unaffected. Similarly, if the PMA 
response is ablated, the PHA response is left unaffected. 
Ficoll-Hypaque-purified lymphocyte preparations  were subjected to further 
fractionation employing the preferential ability of T  lymphocytes to form ro- 
settes with SRBC. When T cells are twice sedimented with SRBC then liberated 
by hypotonic lysis of the erythrocytes, the rosette-forming cell (RFC) population 
of  lymphocytes exceeds 95% pure T lymphocytes, as determined by rerosetting or 
sensitivity to lysis by anti-human T-lymphocyte antiserum. The residual nonro- 
setted population represents a mixture of B lymphocytes and monocytes, as well 
as a few T lymphocytes. As shown in Table I, T-cell enrichment segregates the 
responses to PHA,  Con A, and PWM to the RFC  fraction, but some residual 
response occurs in the nonrosetted population.  Similarly, the PMA response 
resides almost exclusively with the rosetted population. In a further experiment 
with a  single rosette sedimentation, which removes only those T lymphocytes 
with a  high affinity for SRBC  (1/3 to I/2 of the total T  lymphocytes), an even 
greater distinction between PMA and the phytomitogens is observed: only 1% of 
the response to PMA occurred in the non-RFC population in contrast to 60, 45, 
and 68% for the responses to PHA, Con A, and PWM, respectively. These data 462  TOURAINE  ET AL. 
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FIG.  2.  Inactivation of PHA- or PMA-responsive human PBL by BUdR and light treat- 
ment. Experimental protocol: 1st mitegen --* indicates 72-h incubation with no mitogen, 
PMA, or PHA. 10 -3 M BUdR ~  indicates treatment with BUdR and light followed by three 
washes. 2nd mitogen --* indicates a second period of 72-h incubation with no mitegen, PMA, 
or  PHA.  Cultures  were  terminated  on  day  6  and  assayed  for  the  incorporation  of 
[3H]thymidine. Data are expressed as cpm _+  SE. 
TABLE  I 
Proliferative Responses* of Human Lymphocytes Separated by the Rosetting Method 
Mitogens 
Lymphocytes 
None  PMA  PHA  Con  A  PWM 
Unseparated  205 ±  15  5,914  _+  425  36,225  -+ 2,741  14,084  -+ 748  9,032  ±  1,320 
RFC  131 ±  I0  13,931  ±  1,007  23,055  -+  1,069  10,046  ±  846  5,179  ±  944 
RFC-depleted lymphocytes  796  ±  84  1,304  -+ 55  4,294 ±  554  4,077  ±  223  3,077 ±  184 
* Results are lower than those in Fig. 1 and 2 because of the lower specific activity of [ZH]thymidine employed. 
indicate  that  the  PMA-responsive  population  may represent  a  T-cell  subset 
having a high affinity for SRBC. 
Discussion 
The present experiments indicate that PMA is mitogenic for a subpopulation 
of thymus-derived  lymphocytes having  relatively high  affinity for SRBC and 
different  from  those  responsive  to  PHA.  We  have  previously  observed that 
PMA's mitogenic effect is additive to that  of PHA (2),  and that PMA induces 
lymphoblasts that can be distinguished morphologically from those produced by 
PHA in that they are smaller, more vacuolated, and tend to have a more smooth 
or  ruffled  surface  appearance  (2,  9).  We  can  now interpret  these  differences 
between PMA and PHA as resulting principally from their actions to independ- 
ently  activate  two different  lymphocyte subpopulations  in  human  peripheral 
blood.  This  interpretation  does  not  exclude  the  possibility  that  PMA  has  a 
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same cell, as is suggested by experiments employing Con A with lymphocytes 
from different sources and species (4, 5). 
According to current evaluations by surface marker criteria, T lymphocytes 
constitute approximately 75% of the total PBL (8). Of the total PBL, approxi- 
mately 30% are responsive to PHA and by ablative criteria those responding to 
PHA are essentially the same as those responding to ConA (10). In independent, 
unpublished studies of the PMA response of human PBL, we have found that 
the subpopulation responsive to PMA is also distinct from that responsive to Con 
A  and that the PMA-responsive subset is sensitive to lysis by anti-human T- 
lymphocyte antiserum and approximates 20% of the original PBL population. 
The subpopulation responsive to PMA can then be estimated to be one-quarter of 
the T cells, a subpopulation only slightly smaller than that responsive to PHA 
and Con A. 
The functional significance of the PMA responsive T-cell subpopulation re- 
mains to be determined.  Obvious candidates include lymphocytes subserving 
the  functions,  in  addition  to  proliferation,  of cytotoxicity, soluble  mediator 
secretion,  and  helper  or  suppressor  effects.  While  no  direct  information  is 
available, we have observed an extraordinary sensitivity of the PMA-responsive 
population to inhibition with hydrocortisone. 
% inhibition of PHA response 
Hydrocortisone  hemisuccinate  ~g/rnl 
I  I0  i00  1,000 
21%  32%  45%  71% 
%  inhibition of PMA  response  66%  84%  91%  100% 
The PMA  response is sensitive  to 2-3 logs  lower concentration of  hydrocorti- 
sone than the PHA  response. While it  is not clear  whether PMA  may sensitize 
the responder to hydrocortisone or is selecting  a responder that is intrinsically 
more sensitive,  this  finding suggests that  the  subpopulation is  more likely  to  be 
a helper T than an allogeneic responder since these two responses are differen- 
tially  sensitive  to  steroids  (10).  The suggestion  that  the  PMA  responder  is  not  an 
allogeneic responder is further supported by our observation that BUdR  and 
light  ablation of  the PMA-responsive population leaves the mixed lymphocyte 
culture response unaffected (unpublished observation). 
Further insight  into  the functional responses of T cells  subsets is available 
from recent studies in the mouse. These studies employ antisera to cell  surface 
antigens of  the Ly series  to identify  T-lymphocyte subpopulations, a technique 
not yet applicable to human  PBL. Helper activity  is associated with the Lyl 
phenotype and cytotoxic  and suppressor activity  with Ly2,3 (11,  12).  PHA  and 
Con A reactivity  is  associated  with both  phenotypes (13).  These observations are 
further complemented  by the demonstration that in both human  peripheral 
blood and mouse  spleen, those lymphocytes responsive  to mitogens can be 
separated from those responsive  to allogeneic stimulation  (7, 14). Work  is 
needed to resolve  the relation of  those cells  that are responsive to mitogenic, 
allogeneic, or antigenic stimulation to those that respond with proliferative, 
cytotoxic,  and helper  or  suppressor  activity,  and to  interrelate  these  responses  to 
their  species  of  origin,  state  of  differentiation,  and location  in lymphoid tissues 
or blood. 464  TOURAINE  ET AL.  BRIEF DEFINITIVE REPORT 
The basis of the selectivity of PMA action on a  T-cell subpopulation is not 
known.  PMA is  mitogenic  for  3T3  "fibroblasts"  and  for epidermal  cells  and, 
therefore, may be mitogenic for a large variety of cell types (1, 2, 15). It is known 
that  PMA  binds  preferentially  to  plasma  membranes  and  stimulates  mem- 
branes  enzymes  like  adenosine  triphosphatase  and  5'-nucleotidase  (16)  and 
induces increases in transport and cellular levels of cyclic GMP (2,  15). These 
actions are similar to those induced by lectin  mitogens like  PHA and  Con A 
which are thought to bind selectively to plasma membrane receptors. It seems 
likely then,  that the selectivity of PMA action may also reside in specific cell 
surface receptors. 
The  high  affinity of the  PMA-responsive T  lymphocyte for SRBC provides 
some  information  for  understanding  the  selectivity  of PMA  action.  It  is  of 
interest that the population of T cells having high affinity for SRBC forms the 
basis for the  active or early rosette  assay  (17,  18).  It is  also this  population 
(approximately 20-25% of the total PBL population) that is reduced in certain 
autoimmune states and in cancer,  and that,  when reduced, responds to treat- 
ment in vivo and in vitro to stimulation with the thymic hormone preparation 
thymosin (18). It is tempting to predict that PMA may be a useful diagnostic tool 
in probing deficits in the size or proliferative function of this subpopulation. 
Summary 
Phorbol myristate acetate  (PMA) is a  potent mitogen for human peripheral 
blood lymphocytes (PBL) comparable to phytohemagglutinin  (PHA) in potency. 
Inactivation of PHA-responsive lymphocytes by 5'-bromodeoxyuridine and light 
treatment left the PMA response intact and vice versa. Experiments separating 
lymphocytes by rosetting  with sheep erythrocytes  (SRBC) demonstrated  that 
the PMA-responsive lymphocytes segregate with those that have a high affinity 
for SRBC to a greater degree than PHA- or concanavalin A  (Con A)-responsive 
cells.  These results indicate  that  a  PMA-responsive population in human pe- 
ripheral blood resides within the T-lymphocyte population and appears to have a 
high affinity for SRBC and to be distinct from that responding to PHA and Con 
A.  PMA may be useful clinically to assay the  size and function of the  high 
affinity or '~active" rosette population. 
Received for publication  I September 1976. 
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